Want to see AU:ILA full AI Analyst Report?
Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Select Model
Select Model
Rating:53Neutral
Price Target:
AU$0.47
â–²(6.14% Upside)
Action:Reiterated
Date:08/27/26
The score is held down primarily by weak financial performance (persistent losses and ongoing cash burn), partially offset by a low-debt balance sheet and increased equity. Technicals are a positive contributor with the price above key moving averages and supportive momentum indicators. Valuation is penalized due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Debt-Free Balance Sheet
No reported debt limits interest obligations and refinancing exposure, giving Island Pharmaceuticals greater financial flexibility while it funds research and develops its antiviral pipeline.
Negative Factors
Persistent Operating Losses
Widening operating losses indicate that research and corporate costs substantially exceed current income, increasing the funding required before the company can establish sustainable commercial profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
No reported debt limits interest obligations and refinancing exposure, giving Island Pharmaceuticals greater financial flexibility while it funds research and develops its antiviral pipeline.
Read all positive factors
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$139.17M
Dividend YieldN/A
Average Volume (3M)167.41K
Price to Earnings (P/E)―
Beta (1Y)-0.71
Revenue GrowthN/A
EPS Growth-59.29%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding296,096,680
10 Day Avg. Volume123,405
30 Day Avg. Volume167,408
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)7.63
Price to Sales (P/S)0.00
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101...
How the Company Makes Money
null...
Island Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 118.91K | 1.25M | 11.06K | 0.00 |
| Gross Profit | -105.29K | -1.29M | -1.01M | 11.06K | 0.00 |
| EBITDA | -10.51M | -4.07M | -2.82M | -2.82M | -2.61M |
| Net Income | -9.84M | -3.92M | -2.86M | -2.83M | -2.61M |
Balance Sheet | |||||
| Total Assets | 14.00M | 7.49M | 2.56M | 2.05M | 4.90M |
| Cash, Cash Equivalents and Short-Term Investments | 12.87M | 7.25M | 1.66M | 2.00M | 4.79M |
| Total Debt | 0.00 | 0.00 | 421.97K | 0.00 | 0.00 |
| Total Liabilities | 538.52K | 336.43K | 1.05M | 263.85K | 580.73K |
| Stockholders Equity | 13.46M | 7.16M | 1.52M | 1.79M | 4.32M |
Cash Flow | |||||
| Free Cash Flow | -4.83M | -2.77M | -3.16M | -2.71M | -1.88M |
| Operating Cash Flow | -4.83M | -2.77M | -3.16M | -2.71M | -1.88M |
| Investing Cash Flow | -841.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 11.11M | 8.36M | 2.79M | -171.36K | 0.00 |
Island Pharmaceuticals Ltd Technical Analysis
Positive
0.44
Price Trends
0.43
Positive
0.40
Positive
0.41
Positive
Market Momentum
<0.01
Positive
58.12
Neutral
41.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ILA, the sentiment is Positive. The current price of 0.44 is below the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.43, and above the 200-day MA of 0.41, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 58.12 is Neutral, neither overbought nor oversold. The STOCH value of 41.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ILA.
Island Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$139.17M | -13.06 | -95.50% | ― | ― | -59.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$198.79M | -11.04 | -103.42% | ― | ― | 5.88% | |
48 Neutral | AU$160.81M | -1.74 | -1189.87% | ― | 53.78% | -206.24% | |
47 Neutral | AU$171.11M | -5.73 | 362.74% | ― | -22.13% | -108.82% | |
43 Neutral | AU$113.13M | -7.14 | 84.67% | ― | ― | 42.51% | |
42 Neutral | AU$70.74M | -0.89 | -98.86% | ― | ― | -27.73% |
* Healthcare Sector Average
AU:ILA
Island Pharmaceuticals Ltd
0.47
0.17
56.67%
AU:ACW
Actinogen Medical
0.05
0.03
96.30%
AU:PAR
Paradigm Biopharmaceuticals
0.27
-0.01
-3.64%
AU:IMM
Immutep Ltd
0.05
-0.20
-80.41%
AU:DXB
Dimerix Limited
0.29
-0.23
-44.12%
AU:RCE
Recce Pharmaceuticals Ltd.
0.37
-0.08
-17.78%
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals files updated ASX corporate governance statement
Aug 26, 2026
Island Pharmaceuticals Ltd has lodged its updated corporate governance statement for the financial year ended 30 June 2026, confirming that the document is current as of that date and has been approved by the board. The statement is hosted on the ...
Island Pharmaceuticals Posts Larger Loss as Net Tangible Assets Improve in FY2026
Aug 26, 2026
Island Pharmaceuticals reported a sharp increase in income from ordinary activities to $559,080 for the year ended 30 June 2026, up 214.6% from the prior year, reflecting modest revenue generation in its biotech operations. Despite this, the group...
Island Pharmaceuticals boosts Galidesivir supply as Bundibugyo Ebola outbreak escalates
Aug 20, 2026
Island Pharmaceuticals has commissioned a second manufacturing campaign of GMP-grade Galidesivir with PI Health Sciences to materially expand its available drug inventory. The company expects to have around 700 to 800 treatment courses ready by th...
Island Pharmaceuticals Sets October AGM and Board Nomination Deadline
Aug 13, 2026
Island Pharmaceuticals has scheduled its Annual General Meeting for 8 October 2026 in Melbourne, with the agenda to include the re-election of directors as part of its regular corporate governance cycle. The company has set 5:00 p.m. Melbourne tim...
Island Pharmaceuticals Issues New Shares on Option Exercise and Confirms Regulatory Compliance
Aug 11, 2026
Island Pharmaceuticals has issued 180,000 fully paid ordinary shares following the exercise of unlisted options at an issue price of $0.12 per share. The company confirmed that these shares were issued without the need for a disclosure document an...
Island Pharmaceuticals Seeks ASX Quotation for Additional Shares
Aug 11, 2026
Island Pharmaceuticals Ltd, an ASX-listed biopharmaceutical company trading under the code ILA, is engaged in the development of pharmaceutical products. The firm operates within the life sciences sector and uses public equity issuance as a key fu...
Island Pharmaceuticals Targets Filovirus Threats With Galidesivir Strategy
Aug 6, 2026
Island Pharmaceuticals has outlined a dual approach to advance its antiviral candidate Galidesivir as a pan-filovirus medical countermeasure. The strategy is framed against the backdrop of past Ebola outbreaks, highlighting the scale of cumulative...
Island Pharmaceuticals advances Galidesivir program and secures key biodefence approvals
Jul 30, 2026
Island Pharmaceuticals reported strong progress in the June quarter across its flagship Galidesivir program, advancing regulatory, manufacturing and clinical foundations for development under the U.S. FDA’s Animal Rule pathway. The company b...
Island Pharmaceuticals to showcase antiviral pipeline progress at TechKnow Invest Roadshow
Jul 26, 2026
Island Pharmaceuticals has announced that its non-executive chairman Jason Carroll will present at the TechKnow Invest Roadshow in Melbourne and Sydney, providing investors with an update on regulatory and clinical progress. The company will outli...
Island Pharmaceuticals Issues 4 Million Unquoted Options Under New Appendix 3G
Jul 13, 2026
Island Pharmaceuticals has notified the market of the issue of 4,000,000 unquoted options under the ASX Appendix 3G framework. The options, which carry various exercise prices and expiry dates, were issued on 16 April 2026 and represent a new clas...
Island Pharmaceuticals Issues Unquoted Options Under Employee Incentive Scheme
Jul 13, 2026
Island Pharmaceuticals Ltd is an Australian-listed biotechnology company focused on developing pharmaceutical products. The company is traded on the ASX under the ticker ILA and operates within the biopharmaceutical sector, pursuing drug developme...
Island Pharmaceuticals Issues 500,000 Unquoted Options Under Employee Incentive Plan
Jul 13, 2026
Island Pharmaceuticals has issued 500,000 unquoted options under its employee incentive scheme, with these securities expiring on various dates and at various exercise prices, and subject to transfer restrictions until those conditions lapse. The ...
Island Pharmaceuticals Issues 500,000 Unquoted Options Under Employee Incentive Plan
Jul 13, 2026
Island Pharmaceuticals has issued 500,000 unquoted options under its employee incentive scheme, with the options expiring on various dates and carrying various exercise prices. The new securities, recorded under ASX code ILAAL, are subject to tran...
Island Pharmaceuticals Builds Antiviral Portfolio Around Galidesivir
Jul 8, 2026
Island Pharmaceuticals Ltd, listed on the ASX under ticker ILA, operates in the biopharmaceutical sector with a core focus on antiviral treatments for serious viral diseases. Its lead effort is the development of Galidesivir as a multi-filovirus c...
Island Pharmaceuticals Options Lapse, Simplifying Capital Structure
Jul 7, 2026
Island Pharmaceuticals has reported the cessation of 230,000 listed options with an exercise price of $0.21 that expired on 28 April 2026 without being exercised or converted. The expiry modestly streamlines the company’s capital base by rem...
Island Pharmaceuticals Wins Approval to Deploy Galidesivir in Bundibugyo Ebola Outbreak
Jul 6, 2026
Island Pharmaceuticals has secured all necessary government and regulatory approvals in Uganda to use its antiviral candidate Galidesivir on a compassionate basis during the escalating Bundibugyo Ebola epidemic. The program, sponsored by the Ugand...
Island Pharmaceuticals Requests ASX Trading Halt Ahead of Ebola Trial Update
Jul 3, 2026
Island Pharmaceuticals Ltd has requested a trading halt on its ordinary shares on the ASX, effective from 3 July 2026, pending a market announcement. The halt is expected to last until either the commencement of normal trading on 7 July 2026 or th...
Island Pharmaceuticals gains key Singapore patent for ISLA-101 antiviral
Jul 2, 2026
Island Pharmaceuticals has secured a Singapore patent covering the use of its lead antiviral candidate ISLA-101 as a standalone therapy for flavivirus infections, including Dengue, and for Chikungunya virus. The patent, owned by Monash University ...
Island Pharmaceuticals Wins FDA Orphan Status for Marburg Antiviral Galidesivir
Jun 16, 2026
Island Pharmaceuticals has secured a significant regulatory boost with the U.S. Food and Drug Administration granting Orphan Drug Designation to its antiviral candidate Galidesivir for post-exposure prophylaxis of Marburg virus disease. The status...
Island Pharmaceuticals Showcases New PROTECT Study Data at Asia Dengue Summit
Jun 16, 2026
Island Pharmaceuticals Ltd, an Australian antiviral drug developer listed on the ASX, is concentrating on therapies for urgent viral diseases and biosecurity threats through its ISLA-101 and Galidesivir programs. ISLA-101 is being repurposed for d...
Island Pharmaceuticals expands US army research pact to advance Marburg antiviral
Jun 9, 2026
Island Pharmaceuticals has expanded its Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases and The Geneva Foundation, securing access to USAMRIID’s Biosafety Level 4 facilities...
Island Pharmaceuticals advances Galidesivir with new GMP manufacturing deal
Jun 3, 2026
Island Pharmaceuticals has engaged global contract research, development and manufacturing group PI Health Sciences to undertake a GMP manufacturing campaign for its lead antiviral Galidesivir. The program includes analytical method validation, re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.